Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships
Business Insights
September 1, 2008 143 Pages - SKU: RET1918176
|
|
Successful Pharma-Biotech Alliance Strategies
Driving synergies, avoiding failure and managing relationships
"The average value of pharma-biotech deals will almost treble by 2015 as pharma companies focus on gaining exclusive access to high potential technologies via large equity investments..."
In recent years, alliances between pharma and biotech companies have become increasingly common.The potential synergistic benefits to both parties have resulted in over 30% of drugs in clinical trials now being a direct product of such alliances. However, poor deal structure and implemenation continue to contribute to the failure of almost half of these relationships.
‘Successful Pharma-Biotech Alliance Strategies’ is a new report published by Business Insights that provides a detailed examination of the current alliance landscape and analyses the underlying factors that can determine their success or failure. Recent major joint ventures, acquistions and licensing deals are evaluated and the latest trends and developments affecting alliance management are assessed. This report also examines 9 case studies that profile varying approaches to deal structuring and relationship management, and charts the current and future alliance activities of the top ten pharmaceutical companies. Volume and value forecasts for pharma-biotech deals to 2015 are also provided.
Explore the landscape for pharma-biotech alliances and identify the most successful approaches to deal structuring and relationship management...
Use this new report to...
- Benchmark 9 case studies of key alliance management strategies to help you optimize your drug development alliances by identifying successful and unsuccessful approaches across the areas of deal structure, relationship management and monitoring and deal renegotiation.
- Identify the factors that are pivotal to the success or failure of alliances by measuring the influence of a host of variables including management structure, therapeutic area focus, partner locations, drug development stage and manner of partner introduction.
- Assess the competitive positions of potential pharma/biotech partners with this report’s analysis of current and future biotech positions of the top ten pharmaceutical companies and a detailed evaluation of recent major joint ventures, acquistions and licensing deals.
- Understand the future landscape for pharma-biotech alliances with this report’s analysis of the latest trends and developments influencing relationship management in addition to deal trends that include volume and value forecasts for pharma-biotech deals to 2015.
|
- Successful Pharma-Biotech Alliance Strategies
- Executive summary
- Pharma and biotech company synergies
- Overview of pharma-biotech alliances
- Why pharma-biotech alliances fail
- Strategies to manage pharma-biotech alliances
- The future of pharma-biotech alliance management
- Chapter 1 Pharma and biotech company synergies
- Summary
- Background
- The pharmaceutical industry
- The research and development process
- Resources
- Constraints and pressures
- The biotechnology industry
- The research and development process
- Resources
- Constraints and presures
- Drug development today
- More sophisticated science
- More complicated disease targets
- Rapidly escalating costs
- Declining R&D productivity
- Conclusions
- Chapter 2 Overview of pharma- biotech alliances
- Summary
- Introduction
- Evolution of major alliances
- Genentech
- ImClone
- MedImmune
- Current deal trends
- Types of relationships currently undertaken
- Licensing
- Significant recent pharma-biotech licensing deals
- Joint ventures
- Significant recent pharma-biotech joint ventures
- Acquisitions
- Significant recent pharma-biotech acquisitions
- Hostile takeovers
- Offshore alliances
- Japan
- China
- India
- Canada
- Number and value of alliances
- Key therapeutic areas for pharma-biotech alliances
- Conclusions
- Chapter 3 Why pharma-biotech alliances fail
- Summary
- High failure rates
- Symptoms of alliance failure
- Factors that do not affect alliance success
- Main causes of alliance failure
- Management changes
- Culture
- Project organization and expectations
- Alliance goals
- Incentives
- Roles and responsibilities
- Sharing of business processes
- Decision support infrastructure
- Project and alliance leadership
- Harmonization of information technology
- Timelines and budgets
- Alliance expectations
- Other preventable problems
- Technology failure
- The drug approval process
- Drug development success rates
- Case study: Alza and Scios
- Vulnerability by alliance type
- Licensing deals
- Joint ventures
- Acquisitions
- Conclusions
- Chapter 4 Strategies to manage pharmabiotech alliances
- Summary
- Determining alliance success
- Performance measurement
- Alliance goals versus company goals
- Why effective alliance management is crucial
- Key alliance management strategies
- Deal structure
- Case study : Wyeth
- Case study : Novartis
- Relationship managing and monitoring
- Case study : Eli Lilly
- Case study : GlaxoSmithKline
- Exploiting synergies across alliances
- Biologics consolidation
- Case study: AstraZeneca
- Case study: Novartis
- Case study: Pfizer
- Addressing corporate culture
- Case study: WuXi PharmaTech
- Leadership continuity
- Renegotiation
- Third party services
- Conclusions
- Chapter 5 The future of pharma-biotech alliance management
- Summary
- Increasing reliance on biotech by Big Pharma
- Positions of the leading pharmaceutical companies
- AstraZeneca
- Bayer
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
- Weyth
- Deal trends
- Number and value
- Therapeutic areas
- Types of relationships
- Offshore relationships
- Relationship management trends
- Conclusions
- Index
- List of Figures
- Figure 1.1: U.S. NME approvals vs. R&D spend, 1980 - 2007
- Figure 1.2: U.S. R&D spend per NME approval by year, 1990 - 2007
- Figure 2.1: Comparison of key types of pharma-biotech alliances
- Figure 2.2: Volume and value of biolicensing deals, 1997 - 2007
- Figure 3.1: Compounds tested by phase of development, 2008
- Figure 3.2: Pharma-biotech alliance failure trends by alliance type
- Figure 4.1: Pharma, biotech and alliance goals
- Figure 4.2: Roles and responsibilities for alliance personnel
- Figure 4.3: Biologics consolidation vs. alliance consolidation
- Figure 5.1: Volume and value of biolicensing deals, 2005 - 2015 (est.)
- List of Tables
- Table 1.1: Characteristics of pharmaceutical companies and biotechs, 2008
- Table 1.2: Pharma and biotech views of alliances, 2008
- Table 1.3: R&D expenditure within the U.S. and abroad by PhRMA members
- Table 1.4: U.S. R&D spend per NME approved, 1990 - 2007
- Table 2.5: Significant recent pharma-biotech licensing deals
- Table 2.6: Significant recent pharma-biotech licensing deals (continued)
- Table 2.7: Significant recent pharma-biotech licensing deals (continued)
- Table 2.8: Significant recent pharma-biotech licensing deals (continued)
- Table 2.9: Significant recent pharma-biotech licensing deals (continued)
- Table 2.10: Significant recent pharma-biotech acquisitions
- Table 2.11: Significant recent pharma-biotech acquisitions (continued)
- Table 2.12: Significant recent pharma-biotech acquisitions (continued)
- Table 3.13: Cultural characteristics of pharmaceutical companies and biotechs
- Table 4.14: Selected GlaxoSmithKline biotech alliances, 2008
- Table 4.15: Capabilities of selected alliance management specialists
- Table 5.16: Current and future biotech positions of top 10 pharmaceutical companies, 2008
Share this report
Other tasks Related Markets Biopharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
